• Phone: +86 21 63862192
  • Mailbox: info@alphabiopharma.com
  • Shanghai: Unit 02-05, 11/F, East Tower, Raffles City The Bund No.1089 Dong Daming Road, Shanghai 200082, China
  • Beijing: Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing
Company Introduction

ABOUT ALPHA BIOPHARMA

Alpha Biopharma – Specialize in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drugs. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partnership with leading international pharmaceutical companies/R&D institutes.
The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China.

In the field of immunotherapy, by entering into an exclusive license and collaboration agreement with Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, Alpha Biopharma Inc. has expanded its pipeline to manufacture universal "off-the-shelf" Memory NK and CAR-T cells for the treatment of solid tumors, T-cell malignancies, Acute Myeloid Leukemia, and Multiple Myeloma.

Our Philosophy

VISION

Global leading and reliable innovative drug provider

MISSION

Develop innovative drugs to address unmet clinical needs

VALUE

Harmony in diversity / Pursing excellence / Scientific-based spirit / Encouraged to explore

Honors & Recognition